Table 4 Protection of pigs vaccinated with lipoproteins against challenge with virulent A. pleuropneumoniae.

From: Genome-wide screening of lipoproteins in Actinobacillus pleuropneumoniae identifies three antigens that confer protection against virulent challenge

Group

Immunogen

Arithmetic mean ± SD of clinical signs scorea

No. of pigs with lung lesion/total no.

Arithmetic mean ± SD of pleuritis (%)b

Arithmetic mean ± SD of lung lesion scorec

1

APJL_0922

1.60 ± 0.55d,e

3/5

3.80 ± 3.63d

2.40 ± 2.30d

2

APJL_1380

0.80 ± 0.84d

3/5

2.80 ± 2.77d

1.80 ± 1.79d

3

APJL_1976

1.60 ± 0.84e,f

4/5

5.20 ± 3.27d

3.20 ± 1.92d

4

Bacterin

0.60 ± 0.55d

3/5

2.00 ± 1.87d

1.40 ± 1.34d

5

Negative control

3.6 ± 0.55

5/5

30.20 ± 7.46

14.40 ± 2.51

  1. aClinical signs score of challenged pig was assessed as described by Tumamao et al.46: 0, no signs; 1, increased respiration; 2, abdominal breathing; 3, cough; 4, dyspnoea and 5, euthanasia due to severe respiratory distress. The highest clinical signs score of each pig was recorded for evaluation.
  2. bPercentage of pleural surface area exhibiting pleuritis.
  3. cThe lung lesion score was recorded as described previously47. A complete lung was divided into 7 lobes and each was arbitrarily allotted a maximum possible lesion score of 5. Lesions of each lobe were assessed and recorded as a fraction of 5, and the lung lesion score was calculated as the sum of the 7 lobes.
  4. Differences in clinical signs, pleuritis and lung lesion scores among groups were analyzed using ANOVA and followed up with Student’s t-test to compare between any 2 groups. All ANOVA tests were found to be significant (P < 0.001).
  5. For Student’s t-test, dP < 0.001 compared with negative control, eignificant difference relative to bacterin (P < 0.05), fsignificant difference relative to negative control (P < 0.01).
Back to article page